-
CB2R Protection in Iron-Overload Liver Injury
2026-09-29
Deng et al. identify cannabinoid receptor 2 (CB2R) as a regulator of hepatic iron handling that protects against iron overload through coordinated STAT3/hepcidin and Nrf2/FPN1 signaling. The study links hepatocyte iron export with Kupffer-cell redox control, providing a mechanistic framework for evaluating CB2R-directed strategies in iron-related liver disease.
-
ABT-263 Reveals Metabolic Signals Beyond Cell Viability
2026-09-29
Gillette et al. show that ABT-263 alters the optical redox ratio through coordinated changes in NAD(P)H, FAD, mitochondrial polarization, and basal energetics, even when short-term cell viability is preserved. The study provides a cautionary framework for interpreting label-free metabolic imaging alongside orthogonal measurements of proliferation, apoptosis, autophagy, and senescence.
-
Adefovir (GS-0393) Workflows for HBV Research
2026-09-28
Use Adefovir (GS-0393) to test HBV polymerase inhibition or quantify OAT1-mediated transport—two distinct research questions that benefit from different assay controls. This guide covers practical setup, starting conditions, interpretation limits, and what a viral-infection paper on icatibant can—and cannot—contribute to HBV study design.
-
ARCA EGFP mRNA (5-moUTP): Interpreting Signal
2026-09-27
ARCA EGFP mRNA (5-moUTP) provides a fluorescent readout of mRNA delivery and expression. Learn how to interpret reporter signal, design useful controls, and apply findings from lipid nanoparticle research without conflating distinct experimental systems.
-
Lithium–Rab11a Exosomes Drive BMSC Osteogenesis
2026-09-26
The study links lithium-enhanced osteogenesis in bone mesenchymal stem cells (BMSCs) to increased exosomal Wnt10a secretion, Rab11a/Rab11FIP1 trafficking, and β-catenin signaling. It also reports that lithium-conditioned exosomes delivered in GelMA hydrogels promoted bone repair more effectively than control exosomes, suggesting a cell-free strategy that warrants further testing.
-
Atorvastatin: From Target Engagement to Ferroptosis
2026-09-26
Atorvastatin is an HMG-CoA reductase inhibitor whose effects extend from mevalonate-pathway biology to emerging ferroptosis research in hepatocellular carcinoma. This article examines what recent evidence establishes, what it does not, and how to design experiments that distinguish pathway engagement from a cell-death phenotype.
-
4-Ethylphenyl Sulfate: From Signal to Strategy
2026-09-25
4-Ethylphenyl sulfate links renal metabolite retention with emerging gut microbiota-brain interaction research. This article outlines how translational teams can move from biomarker observation to controlled biological testing and adsorption studies—while keeping model-specific evidence and clinical claims in perspective.
-
SB-505124 Hydrochloride: Practical Research Workflows
2026-09-25
Use SB-505124 hydrochloride to dissect ALK4/5/7-dependent TGF-β and activin signaling, connect receptor blockade to fibroblast activation readouts, and build controlled follow-up experiments in tissue models. The workflows emphasize pathway engagement, vehicle and viability controls, and a clear distinction between established fibrosis applications and exploratory cancer-cell mechanics studies.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-09-24
A 2026 study reports mannose-modified lipid nanoparticles designed to deliver EPO mRNA to CD206-enriched macrophages and microglia at spinal cord injury lesions. In mice, the approach was associated with reduced neuroinflammation and ferroptosis-related damage, preserved neural structures, and improved motor recovery, while highlighting the need to establish dosing, biodistribution, and translational feasibility.
-
MMP7 Links EMT to Liver Fibrosis in Biliary Atresia
2026-09-24
This study connects elevated MMP7 with liver fibrosis in biliary atresia and identifies an E-cadherin/β-catenin route by which MMP7 can promote epithelial–mesenchymal transition in biliary epithelial cells. Patient samples, GEO-based enrichment analysis, cell experiments, and a chronic mouse model provide converging evidence for MMP7 as a candidate antifibrotic target, while leaving important questions about clinical translation and the consequences of EMT unresolved.
-
Torin2: Selective mTOR Inhibitor for Cancer Research
2026-09-23
Torin2 is a potent, selective mTOR inhibitor with a reported EC50 of 0.25 nM and oral bioavailability. Its applications include cancer research, medullary thyroid carcinoma models, pathway studies, and apoptosis assay design, while its off-target profile and assay conditions require careful interpretation.
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-09-23
Oh et al. developed and validated a scalable human induced pluripotent stem cell-derived sensory neuron system that supports HSV-1 latency and reactivation. The model combines neuronal functional characterization with virological, transcriptional, and chromatin-based criteria, providing a human platform for studying neuron-intrinsic mechanisms of HSV-1 persistence.
-
MK-2206 Dihydrochloride in HCC Angiogenesis
2026-09-22
Explore how MK-2206 dihydrochloride can help dissect extracellular-vesicle-driven PI3K/Akt signaling in hepatocellular carcinoma angiogenesis. This mechanistic guide connects Akt inhibition with endothelial assays, VEGFA biology, and apoptosis interpretation.
-
Gap19: Selective Connexin 43 Hemichannel Blocker
2026-09-21
Gap19 enables targeted Cx43 hemichannel inhibition while preserving gap junction channel function, making it useful for neuroglial, astrocyte, and inflammation-focused assays. This workflow-led guide connects ATP-release measurements, ischemia models, and Cx43/NF-κB signaling experiments with practical optimization and troubleshooting advice.
-
Sulfaphenazole Restores Perfusion in Ischemic Skin Injury
2026-09-21
Turner et al. show that sulfaphenazole reduces pressure- and thermal-injury severity in an ischemia–reperfusion model by rapidly restoring tissue perfusion and limiting hypoxia, inflammation, fibrosis, and impaired healing. The study supports CYP 2C inhibition as a vascular-protective strategy, while its mouse-model design also clarifies the evidence needed for translation to human wound care.